When chemotherapy or radiation alone isn’t cutting it, immunotherapy has become one of the more hopeful chapters in modern cancer care. Over the past few years, a growing number of patients have started looking seriously at immunotherapy treatment in India.  

In this blog, we walk you through how immunotherapy actually works, which cancers respond to it, what it realistically costs, and how to plan your trip to India without wasting time or money. 

What Immunotherapy Actually Does? 

Chemotherapy attacks any fast-dividing cell, cancerous or not, which is why it comes with harsh side effects. Immunotherapy takes a different approach: it retrains or unblocks your own immune system so it can find and destroy cancer cells on its own.  

The most widely used class is checkpoint inhibitors — drugs like pembrolizumab, nivolumab, and durvalumab. Tumors often display a protein called PD-L1 that tells nearby immune cells to stand down. These drugs block that signal, so the immune system can recognize and attack the tumor again. For certain blood cancers, a more advanced option called CAR-T cell therapy is now available at a handful of Indian centers. 

Why Patients Are Choosing India? 

Several practical factors explain the rise in cancer treatment in India for international patients: 

In-house biomarker testing. PD-L1, MSI-H, and TMB testing — the tests that decide if a patient even qualifies for immunotherapy — are done locally at major cancer centers, so treatment can start within days of arrival rather than weeks.  

Accredited infrastructure. Many hospitals offering advanced cancer treatment in India carry NABH or JCI accreditation, meaning their protocols are audited against international patient-safety benchmarks.  

Shorter waiting periods. Compared to overloaded public health systems in many home countries, private oncology units in India can usually schedule a first infusion within one to two weeks of a confirmed diagnosis.  

Multidisciplinary tumor boards. Decisions on drug combinations are typically reviewed by a panel of oncologists. 

Dedicated international patient services. Visa letters, airport transfers, interpreter support, and package quotes are handled by Curebridge, which matters a great deal when you’re managing this from another country. 

Which Cancers Respond to Immunotherapy? 

Not every cancer, and not every patient, is a candidate. Immunotherapy for cancer patients in India is most established for: 

• Non-small cell lung cancer 

• Melanoma 

• Kidney and bladder cancers 

• Head and neck cancers 

• Certain Hodgkin and non-Hodgkin lymphomas (often with CAR-T) 

• MSI-high colorectal and gastric cancers

Therefore, eligibility comes down to a proper pathology work-up. A good oncology team will be upfront if immunotherapy isn’t the right fit and will recommend chemotherapy, targeted therapy, or a combination instead. 

Immunotherapy Cost in India 

This is usually the first question families ask, and fair enough. Standard checkpoint inhibitors like pembrolizumab or nivolumab typically run between roughly ₹1.5 lakh and ₹4.5 lakh (about $1,800 to $5,500) per cycle in India, with most protocols involving anywhere from four to twelve cycles depending on the cancer type and how the patient responds. CAR-T cell therapy, since each dose is manufactured individually for the patient, sits in a much higher bracket. 

For context, a single dose of a checkpoint inhibitor in the United States can carry a list price anywhere from roughly $10,000 to $25,000 before insurance. Even after adding flights, accommodation, and a facilitation fee, the overall immunotherapy cost in India for a full course generally remains well below what the same treatment costs in Western countries.  

What the Process Actually Looks Like? 

• Remote review. Send existing biopsy, imaging, and blood work to a hospital or coordinator for an initial opinion. This alone can rule in or rule out immunotherapy before booking a flight. 
• Confirmatory testing. Biomarker tests are repeated or confirmed on arrival if the existing samples aren’t sufficient. 
• Tumor board decision. A panel of oncologists agrees on the drug, dosage, and number of cycles. 
• Treatment and monitoring. Cycles are typically spaced two to three weeks apart, with scans every few cycles to track response. 
• Ongoing care. Some patients complete the full course during one visit; others return home after the first few cycles and continue under shared care with their local oncologist. 

A Few Things Worth Asking Before You Book 

• Ask whether the recommended drug is the original branded version or a licensed India-manufactured version. Both are approved for use, but the price difference can be significant. 

• Ask why a particular combination (say, immunotherapy plus chemotherapy) was chosen over immunotherapy alone. A good oncologist will explain the reasoning in plain terms. 

• Confirm biomarker testing is done before you travel, if reports allow it, so you’re not paying for a diagnostic delay after arrival. 

• Get the full package cost in writing — drug cost, hospital stay, tests, and coordinator fees separately — rather than a single rounded figure. 

If you’d rather have someone put this together for you instead of chasing quotes across hospitals, Curebridge can arrange an online oncologist consultation and a written cost breakdown before you commit to travel. 

The Honest Bottom Line 

Immunotherapy has changed outcomes for many patients, but it isn’t a guarantee, and it isn’t right for every diagnosis. What India genuinely offers is fast biomarker testing, experienced oncology teams, transparent packages, and a cost structure that makes a long treatment course financially possible for far more families than it used to be. 

If you’re exploring immunotherapy treatment in India, Curebridge helps you make informed decisions with confidence. Get in touch with us! 

FAQs 

1. Is immunotherapy treatment in India as effective as treatment in the US or UK?  

Response rates depend on the cancer type, stage, and biomarker profile — not the country. The same drugs (pembrolizumab, nivolumab, and others) are used in India, following the same international dosing protocols. 

2. How do I know if I qualify for immunotherapy?  

Qualification is based on biomarker tests such as PD-L1 expression, microsatellite instability (MSI), and tumor mutational burden (TMB). Your oncologist reviews these results alongside your cancer type and stage before recommending immunotherapy. 

3. What is the typical immunotherapy cost in India per cycle?  

Standard checkpoint inhibitor cycles generally range from ₹1.5 lakh to ₹4.5 lakh (roughly $1,800 to $5,500), while CAR-T cell therapy costs considerably more due to its personalized manufacturing process. 

4. How many cycles of immunotherapy are usually needed?  

Most protocols involve four to twelve cycles, spaced two to three weeks apart, though the exact number depends on cancer type, stage, and how well the patient responds on follow-up scans. 

5. Can I get a second opinion before traveling to India?  

Yes. Most hospitals and patient coordinators offer remote review of existing biopsy and imaging reports, which can confirm (or rule out) immunotherapy as an option before you book travel.